Vivos Long Term Debt vs Short Term Debt Analysis

VVOS Stock

USD 4.55 0.06 1.30%

Vivos Therapeutics financial indicator trend analysis is much more than just breaking down Vivos Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vivos Therapeutics is a good investment. Please check the relationship between Vivos Therapeutics Long Term Debt and its Short Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Long Term Debt vs Short Term Debt

Long Term Debt vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vivos Therapeutics Long Term Debt account and Short Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Vivos Therapeutics' Long Term Debt and Short Term Debt is -0.5. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Vivos Therapeutics, assuming nothing else is changed. The correlation between historical values of Vivos Therapeutics' Long Term Debt and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Vivos Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Long Term Debt i.e., Vivos Therapeutics' Long Term Debt and Short Term Debt go up and down completely randomly.

Correlation Coefficient

-0.5

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Vivos Therapeutics has held for over one year. Long-term debt appears on Vivos Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Vivos Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Short Term Debt

Most indicators from Vivos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vivos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.At this time, Vivos Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 1.85 in 2024, whereas Selling General Administrative is likely to drop slightly above 21.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	14K	1.2M	1.4M	1.4M
Depreciation And Amortization	733K	669K	621K	549.9K

Interest Expense Depreciation And Amortization

Vivos Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.24	0.84	0.61	0.83	0.58	0.68	0.27	0.61	-0.92	-0.48	0.27	0.94	-0.03	0.47	0.49	-0.59	0.94	0.72	-0.6	0.67	0.49	-0.32	0.88	0.65	0.51
Short Long Term Debt Total	0.24		0.52	0.88	-0.21	0.56	0.4	0.48	0.86	0.03	-0.6	0.71	0.1	0.29	0.75	0.77	-0.8	0.1	0.09	-0.82	0.47	0.71	0.39	0.47	0.53	0.9
Other Current Liab	0.84	0.52		0.86	0.5	0.74	0.81	0.49	0.83	-0.68	-0.74	0.67	0.74	0.17	0.71	0.75	-0.88	0.74	0.47	-0.88	0.9	0.81	0.1	0.87	0.83	0.82
Total Current Liabilities	0.61	0.88	0.86		0.16	0.71	0.66	0.52	0.98	-0.37	-0.74	0.76	0.48	0.22	0.86	0.9	-0.95	0.48	0.34	-0.97	0.76	0.84	0.25	0.76	0.74	0.98
Total Stockholder Equity	0.83	-0.21	0.5	0.16		0.15	0.3	-0.03	0.17	-0.97	-0.02	-0.16	0.94	-0.29	0.14	0.08	-0.09	0.94	0.84	-0.09	0.36	0.05	-0.6	0.6	0.3	0.04
Other Liab	0.58	0.56	0.74	0.71	0.15		0.96	0.89	0.69	-0.27	-0.98	0.85	0.34	0.74	0.29	0.4	-0.87	0.34	-0.06	-0.81	0.85	0.91	0.53	0.76	0.95	0.77
Net Tangible Assets	0.68	0.4	0.81	0.66	0.3	0.96		0.83	0.66	-0.41	-0.95	0.77	0.46	0.66	0.29	0.39	-0.82	0.46	0.02	-0.78	0.9	0.87	0.43	0.83	0.96	0.7
Property Plant And Equipment Net	0.27	0.48	0.49	0.52	-0.03	0.89	0.83		0.52	-0.03	-0.9	0.87	0.09	0.93	0.08	0.14	-0.68	0.09	-0.28	-0.6	0.79	0.85	0.77	0.59	0.89	0.63
Current Deferred Revenue	0.61	0.86	0.83	0.98	0.17	0.69	0.66	0.52		-0.37	-0.73	0.71	0.48	0.23	0.87	0.89	-0.92	0.48	0.34	-0.95	0.74	0.8	0.2	0.82	0.73	0.95
Net Debt	-0.92	0.03	-0.68	-0.37	-0.97	-0.27	-0.41	-0.03	-0.37		0.17	0.0	-0.99	0.28	-0.35	-0.31	0.3	-0.99	-0.87	0.3	-0.5	-0.22	0.52	-0.71	-0.42	-0.25
Retained Earnings	-0.48	-0.6	-0.74	-0.74	-0.02	-0.98	-0.95	-0.9	-0.73	0.17		-0.91	-0.24	-0.76	-0.36	-0.46	0.9	-0.24	0.15	0.85	-0.87	-0.95	-0.63	-0.73	-0.94	-0.81
Accounts Payable	0.27	0.71	0.67	0.76	-0.16	0.85	0.77	0.87	0.71	0.0	-0.91		0.09	0.72	0.43	0.51	-0.88	0.09	-0.19	-0.83	0.84	0.97	0.79	0.54	0.86	0.86
Cash	0.94	0.1	0.74	0.48	0.94	0.34	0.46	0.09	0.48	-0.99	-0.24	0.09		-0.24	0.45	0.41	-0.39	1.0	0.88	-0.41	0.56	0.31	-0.47	0.76	0.49	0.36
Non Current Assets Total	-0.03	0.29	0.17	0.22	-0.29	0.74	0.66	0.93	0.23	0.28	-0.76	0.72	-0.24		-0.23	-0.14	-0.44	-0.24	-0.59	-0.35	0.53	0.65	0.85	0.29	0.68	0.37
Non Currrent Assets Other	0.47	0.75	0.71	0.86	0.14	0.29	0.29	0.08	0.87	-0.35	-0.36	0.43	0.45	-0.23		0.98	-0.71	0.45	0.5	-0.78	0.48	0.51	-0.06	0.56	0.37	0.79
Other Assets	0.49	0.77	0.75	0.9	0.08	0.4	0.39	0.14	0.89	-0.31	-0.46	0.51	0.41	-0.14	0.98		-0.79	0.41	0.4	-0.85	0.52	0.58	0.01	0.58	0.43	0.84
Long Term Debt	-0.59	-0.8	-0.88	-0.95	-0.09	-0.87	-0.82	-0.68	-0.92	0.3	0.9	-0.88	-0.39	-0.44	-0.71	-0.79		-0.39	-0.13	0.99	-0.85	-0.94	-0.43	-0.76	-0.86	-0.97
Cash And Short Term Investments	0.94	0.1	0.74	0.48	0.94	0.34	0.46	0.09	0.48	-0.99	-0.24	0.09	1.0	-0.24	0.45	0.41	-0.39		0.88	-0.41	0.56	0.31	-0.47	0.76	0.49	0.36
Net Receivables	0.72	0.09	0.47	0.34	0.84	-0.06	0.02	-0.28	0.34	-0.87	0.15	-0.19	0.88	-0.59	0.5	0.4	-0.13	0.88		-0.18	0.21	-0.01	-0.7	0.48	0.1	0.19
Good Will	-0.6	-0.82	-0.88	-0.97	-0.09	-0.81	-0.78	-0.6	-0.95	0.3	0.85	-0.83	-0.41	-0.35	-0.78	-0.85	0.99	-0.41	-0.18		-0.8	-0.9	-0.35	-0.76	-0.8	-0.98
Common Stock Total Equity	0.67	0.47	0.9	0.76	0.36	0.85	0.9	0.79	0.74	-0.5	-0.87	0.84	0.56	0.53	0.48	0.52	-0.85	0.56	0.21	-0.8		0.92	0.44	0.83	0.96	0.79
Common Stock Shares Outstanding	0.49	0.71	0.81	0.84	0.05	0.91	0.87	0.85	0.8	-0.22	-0.95	0.97	0.31	0.65	0.51	0.58	-0.94	0.31	-0.01	-0.9	0.92		0.64	0.7	0.94	0.91
Non Current Liabilities Total	-0.32	0.39	0.1	0.25	-0.6	0.53	0.43	0.77	0.2	0.52	-0.63	0.79	-0.47	0.85	-0.06	0.01	-0.43	-0.47	-0.7	-0.35	0.44	0.64		0.01	0.5	0.42
Other Current Assets	0.88	0.47	0.87	0.76	0.6	0.76	0.83	0.59	0.82	-0.71	-0.73	0.54	0.76	0.29	0.56	0.58	-0.76	0.76	0.48	-0.76	0.83	0.7	0.01		0.84	0.71
Other Stockholder Equity	0.65	0.53	0.83	0.74	0.3	0.95	0.96	0.89	0.73	-0.42	-0.94	0.86	0.49	0.68	0.37	0.43	-0.86	0.49	0.1	-0.8	0.96	0.94	0.5	0.84		0.79
Total Liab	0.51	0.9	0.82	0.98	0.04	0.77	0.7	0.63	0.95	-0.25	-0.81	0.86	0.36	0.37	0.79	0.84	-0.97	0.36	0.19	-0.98	0.79	0.91	0.42	0.71	0.79

Click cells to compare fundamentals

Vivos Therapeutics Account Relationship Matchups

Vivos Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.6M	25.3M	33.7M	13.7M	10.7M	18.2M
Short Long Term Debt Total	3.7M	1.3M	1.6M	2.4M	2.0M	2.1M
Other Current Liab	1.4M	3.2M	2.9M	1.6M	2.5M	2.2M
Total Current Liabilities	9.1M	7.8M	7.5M	6.8M	7.3M	7.5M
Total Stockholder Equity	(2.9M)	16.9M	25.5M	4.8M	411K	390.5K
Property Plant And Equipment Net	1.1M	871.6K	2.8M	4.8M	4.7M	2.9M
Current Deferred Revenue	2.9M	2.9M	2.4M	2.9M	2.1M	2.6M
Net Debt	3.2M	(16.9M)	(22.4M)	(1.1M)	352K	369.6K
Retained Earnings	(23.3M)	(35.3M)	(55.6M)	(79.5M)	(93.1M)	(88.4M)
Accounts Payable	1.1M	781K	920K	1.4M	2.1M	1.2M
Cash	469.4K	18.2M	24.0M	3.5M	1.6M	1.6M
Non Current Assets Total	5.6M	4.9M	6.4M	8.3M	8.3M	7.3M
Non Currrent Assets Other	1.1M	1.1M	356K	374K	307K	433.5K
Cash And Short Term Investments	469.4K	18.2M	24.0M	3.5M	1.6M	1.6M
Net Receivables	956.0K	1.5M	1.7M	457K	202K	191.9K
Common Stock Shares Outstanding	727.7K	728.4K	849.3K	920.5K	1.2M	899.6K
Liabilities And Stockholders Equity	7.6M	25.3M	33.7M	13.7M	10.7M	18.2M
Non Current Liabilities Total	1.4M	587.1K	641K	2.1M	3.0M	1.6M
Other Current Assets	295.0K	1.3M	1.6M	1.4M	616K	997.7K
Other Stockholder Equity	20.3M	50.8M	81.2M	84.3M	93.5M	63.7M
Total Liab	10.5M	8.4M	8.2M	8.9M	10.3M	9.1M
Net Invested Capital	766.5K	18.2M	26.8M	4.8M	411K	390.5K
Property Plant And Equipment Gross	1.1M	871.6K	4.1M	6.5M	7.0M	3.8M
Total Current Assets	2.0M	20.4M	27.3M	5.4M	2.5M	2.3M
Net Working Capital	(7.1M)	12.6M	19.8M	(1.4M)	(4.8M)	(4.6M)
Short Term Debt	3.7M	867.0K	1.3M	838K	474K	450.3K
Intangible Assets	689.2K	270.1K	341K	302K	420K	421.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC